666747-06-4 Usage
Description
2,4-Dibromobenzyl Alcohol is a halogenated organic compound characterized by the presence of two bromine atoms attached to a benzyl alcohol structure. It is known for its unique chemical properties and potential applications in various fields.
Uses
Used in Proteomics Research:
2,4-Dibromobenzyl Alcohol is used as a halogenated compound for proteomics research, where it aids in the identification and analysis of proteins and their functions within biological systems.
Used in Pharmaceutical Industry:
2,4-Dibromobenzyl Alcohol is used as an intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents. Its unique structure and properties make it a valuable component in the creation of innovative medications.
Check Digit Verification of cas no
The CAS Registry Mumber 666747-06-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,6,7,4 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 666747-06:
(8*6)+(7*6)+(6*6)+(5*7)+(4*4)+(3*7)+(2*0)+(1*6)=204
204 % 10 = 4
So 666747-06-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H6Br2O/c8-6-2-1-5(4-10)7(9)3-6/h1-3,10H,4H2
666747-06-4Relevant articles and documents
Synthetic method 2 and 4 - dibromobenzyl alcohol
-
, (2021/10/11)
The invention provides 2-4 - dibromobenzyl alcohol synthesis method, and the specific steps are as follows: S1, 2, 4 - dibromotoluene is brominated 2 and 4 - dibromobenzyl bromide in a radical initiator. S2 represents 2, 4 - dibromobenzylacetate in acetat
IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Paragraph 0079; 0080, (2016/08/29)
The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.